PYPD (polypid.com) Net earnings per share (EPS TTM)

polypid.com (PYPD) - corporate logo

PolyPid Ltd. maintains a stable output of antibacterial agents through its own automated plants in Israel. The 12-month EPS trend captures this driver, where -1.47 reflects the latest metric level. The development of unique local drug delivery systems reduces postoperative risks, while future pricing power relies on patents in the field of sustained-release antibiotics.

PYPD (PolyPid Limited) Net earnings per one share for the last twelve months history from 07/04/2022 to 11/11/2026

PolyPid Ltd (PYPD) - metric breakdowns and financial figures

- current quotes and average value forecast:
Price Chart PolyPid Limited|PYPD - Broker Consensus Forecast
- business market valuation indicators:
Market Capitalization PolyPid Ltd.|PYPD - Full Business Value
- business book valuation details:
Book Value per Share PolyPid|PYPD - Total Stockholders' Equity|Market Capitalization to Book Value Ratio polypid.com|PYPD - Cumulative Company Assets
- debt and solvency information:
Total Debt to Equity Ratio PolyPid Ltd.|PYPD - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital PolyPid Limited|PYPD - Company Total Debt Obligations|Debt to Book Capitalization Ratio PolyPid Ltd.|PYPD - Long-Term Debt|Company Short-Term Debt PolyPid|Quick Liquidity polypid.com
- net income and valuation multiples indicators:
PYPD - Net Financial Result|Expected Profit PolyPid Ltd.|PYPD - Market Cap to Net Income|Future Price to Earnings PolyPid Limited|PYPD - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PolyPid Ltd.|PYPD - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months PolyPid|PYPD - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months polypid.com|PYPD - Earnings per share trend in current year|Earnings growth forecast for next year PolyPid Ltd.
Fundamental company analysis:PYPD - polypid.com
Flagship merchandise of PolyPid Ltd

Investors are assessing the resilience of PolyPid Ltd. (PYPD) through the dynamics of real earnings per share. This metric is calculated as the ratio of total annual net income to the number of shares outstanding. By analyzing the current level of annual net income per share, one can determine the monetization efficiency of the PLEXEL platform. Growth in this indicator confirms the commercial success of the closed-loop therapy, while a downward trend signals risks of capital loss.

Main competitors

SMMT - Earnings per share for the last twelve months|MRNA (modernatx.com) - Earnings per share for the last 12 months|PCVX: Net earnings per share (EPS TTM)|Earnings per one share for the last 12 months TARS (Tarsus Pharmaceuticals Inc)|CRMD (CorMedix Corp) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Seres Therapeutics, Inc MCRB|Net earnings per share (EPS TTM) SPRO|Net earnings per share for the last 12 months scynexis.com SCYX|AN2 Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the last four quarters LSB (LakeShore Biopharma Co., Ltd.)|Iterum Therapeutics, plc - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BiomX Inc. PHGE|soligenix.com (SNGX) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months 60 Degrees Pharmaceuticals, Inc. (SXTP)|Earnings per share for the last twelve months Oragenics|Earnings per share for the last 12 months OPGN (OpGen Inc)